Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 3 years of Accumulated Depreciation data on record, last reported at $1.4 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation fell 16.52% year-over-year to $1.4 million; the TTM value through Dec 2024 reached $1.4 million, down 16.52%, while the annual FY2024 figure was $1.4 million, 16.52% down from the prior year.
  • Accumulated Depreciation reached $1.4 million in Q4 2024 per AMLX's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $1.6 million in Q4 2023 and bottomed at $540000.0 in Q4 2022.
  • Average Accumulated Depreciation over 3 years is $1.2 million, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 201.48% in 2023, then fell 16.52% in 2024.
  • A 3-year view of Accumulated Depreciation shows it stood at $540000.0 in 2022, then surged by 201.48% to $1.6 million in 2023, then decreased by 16.52% to $1.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $1.4 million in Q4 2024, $1.6 million in Q4 2023, and $540000.0 in Q4 2022.